

## **Driven by its unique technology, the BioTech GreenTropism is taking new steps with a view to marketing its solutions internationally.**

**After making a name for itself during the health crisis with its ultra-fast tests, the French startup, which is currently in the process of raising funds, is aiming to become a reference in in vitro diagnostics.**

### **An innovative, proven technology to meet the challenges of pathogen detection.**

The company founds its savoir-faire on spectroscopy<sup>1</sup> associated with Artificial Intelligence (AI). Spectral analysis allows the detection, classification, or quantification of samples, and the processing of these complex data (in record time, in order to determine the status of a sample, or to quantify a molecule of interest) is made possible by AI, through the work of the company's data scientists. *"The combination of spectroscopy and AI is an innovative method of analysis, whose effectiveness has been demonstrated to large groups that are customers of our solutions,"* says Roland Carbonnel, CEO. Its development in the form of a medical platform aims to provide biologists and clinicians with results on the infection status of their patients - up to 3 pathogens, bacteria and viruses, simultaneously - in less than 3 minutes. The same automated device is used in veterinary diagnostics for continuous monitoring of the absence or presence of pathogens in livestock, and in wastewater and bathing water diagnostics to track the evolution of any contamination. *"These are real public health issues to which we can provide answers"* explains Roland Carbonnel, *"and I'm thinking in particular of bathing water, with the upcoming 2024 Olympic Games in Paris, where several swimming events will take place in the Seine and Marne rivers"*. Especially since GreenTropism's Inno4diag project to monitor the water at whitewater swimming competition sites (Seine and Bassin de la Villette) has been selected by the BPI and the Île-de-France Region. Thanks to prestigious partnerships: APHP, IRBA (Institute of Biomedical Research of the Army), TLL Singapore, University of Lisbon, Biogroup, Hôpital St Joseph, etc., the company has been able to accelerate its development, with the ambition of marketing its products internationally, and even more, to become a reference in in vitro diagnostics.

### **An ambitious company that is developing on solid foundations.**

Since its creation, GreenTropism has been building its credibility to grow and export. The company has filed 22 patents - in 5 different families - to protect and secure its operating monopoly and its *"unique"* technology, from which its ultra-fast diagnostic platform is derived; *"to date, no other technology can combine the analytical performance, flexibility in terms of sample types, speed and convenience of tests such as those offered by GreenTropism: The results are delivered on the spot, in less than 3 minutes, which offers the possibility to perform large-scale tests, in airports for example"* adds Anthony Boulanger, CTO and founder of the company. At the same time, GreenTropism has just obtained the LNE - Artificial Intelligence certification, becoming the first company in the field of diagnosis to have its AI certified: *"Beyond our expertise, it is our know-how and our exemplary nature that we wanted to be recognized, namely an AI designed, developed and used with mastery and transparency"* underlines Roland Carbonnel, CEO, while regulations in this field - currently almost non-existent - should flourish in the near future. It was therefore voluntarily and with full knowledge of the facts that the company took part in the certification audit in order to open the doors to the US, which accounts for 40% of the world market for infectious disease diagnostics, for a market estimated at more than 30 billion euros. These guarantees of reliability are highly appreciated by the company's French and international investors, especially as it is currently in the process of raising Series A round of financing.

### **About GreenTropism.**

GreenTropism develops innovative in vitro diagnostic tests using Artificial Intelligence and spectrometers for medical, veterinary and water diagnostic applications. GreenTropism commercializes its AI in industry 4.0, including bioproductions, in Europe and the United States. The company is based in Paris and Rouen (Research Laboratories) and has 15 employees.

<sup>1</sup> Science of the study of the interaction between light and matter.

#### **Press inquiries**

marion.bloch@greentropism.com  
+33616852273

#### **GreenTropism's LNE - Artificial Intelligence certification**

Certificat n° 38587  
www.lne.fr

**Website** : [www.greentropism.com](http://www.greentropism.com)

**LinkedIn** : [@greentropism](https://www.linkedin.com/company/greentropism)

**Twitter** : [@greentropism](https://twitter.com/greentropism)